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INTRODUCTION: Exposure to ionizing radiation at mammography screening may cause breast cancer. Because the radiation risk
increases with lower exposure age, advancing the lower age limit may affect the balance between screening benefits and risks.
The present study explores the benefit–risk ratio of screening before age 50.
METHODS: The benefits of biennial mammography screening, starting at various ages between 40 and 50, and continuing up to age 74
were examined using micro-simulation. In contrast with previous studies that commonly used excess relative risk models, we assessed
the radiation risks using the latest BEIR-VII excess absolute rate exposure-risk model.
RESULTS: The estimated radiation risk is lower than previously assessed. At a mean glandular dose of 1.3mGy per view that was
recently measured in the Netherlands, biennial mammography screening between age 50 and 74 was predicted to induce 1.6 breast
cancer deaths per 100000 women aged 0–100 (range 1.3–6.3 extra deaths at a glandular dose of 1–5mGy per view), against 1121
avoided deaths in this population. Advancing the lower age limit for screening to include women aged 40–74 was predicted to
induce 3.7 breast cancer deaths per 100000 women aged 0–100 (range 2.9–14.4) at biennial screening, but would also prevent
1302 deaths.
CONCLUSION: The benefits of mammography screening between age 40 and 74 were predicted to outweigh the radiation risks.
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Each year, millions of women in Europe have a screening
mammogram. This may reduce the risk of dying from breast
cancer by up to 50% (Allgood et al, 2008; Puliti et al, 2008; Otto
et al, 2010). It may, on the other hand, also cause breast cancer and
breast cancer deaths due to ionizing X-ray radiation. It has been
shown that the risk of tumour induction is proportional to the
dose of radiation absorbed in the breast (Boice et al, 1979; Land,
1980; Land et al, 1980; Howe and McLaughlin, 1996; Little et al,
2008; Henderson et al, 2010). Although radiation doses at
mammography are much lower than the doses for which cancer
induction is directly observed (Preston et al, 2002), screening a
large population on a regular basis has the potential to harm.
Most nevertheless agree that the benefits of screening outweigh
its radiation risks; in particular for women aged 50–69. For annual
screening between age 40 and 49, the risks may also be justified,
provided that a mortality reduction of at least 20% is obtained and
the dose is sufficiently small (Mattsson et al, 2000; Berrington de
Gonzalez and Reeves, 2005). The average denser breasts and faster
growing tumours in this age group, however, may substantially
reduce the screening effectiveness compared with older women. At
the same time, the radiation risks increase with younger exposure
age (Preston et al, 2002). Recently, the UK Age Trial showed a non-
significant 24% breast cancer mortality reduction in women aged
40–48 that were annually screened (Moss et al, 2006). Based on
these findings, we compared radiation risks to the effects of breast
cancer screening, starting at various screening ages between 40 and
50 and continuing up to age 74.
For our analyses, the most recent exposure-risk model is used:
the BEIR-VII model. This model differs from previous models with
regard to the shape of the dose–response relation: at very low
(mammography) doses, the model is adjusted with a dose and
dose-rate effectiveness factor (DDREF). It is an additive instead of
a multiplicative model, which until recently had been the standard
model for risk estimations. We will calculate radiation risks using
new estimates for the average glandular dose that were measured
in the Dutch nationwide screening programme (Zoetelief et al,
2006), and explore the threshold for a positive benefit–risk
balance.
MATERIALS AND METHODS
Two models were used to estimate the ratio of screening benefits
vs radiation risks: the micro-simulation analysis model MISCAN
(de Koning et al, 1995; Groenewoud et al, 2004) that estimates the
benefits of mammography screening, and the radiation risk model
of the 7th Biological Effects of Ionizing Radiation committee
(BEIR-VII) (National Research Council of the National Academies,
2006).
MISCAN simulates the natural course of breast cancer in the
absence of screening: from its early onset to, eventually, death
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impact of screening on the natural history. In short, MISCAN is a
Markov-like stage transition model, in which a lesion progresses
through the successive preclinical invasive TNM stages T1a, T1b,
T1c and T2þ. Preclinical invasive cancer may or may not be
preceded by preclinical DCIS. In the absence of screening, a lesion
can grow from one preclinical stage to the next or become
symptomatic. With screening, a preclinical lesion can also be screen
detected. The onset rate, transition probabilities between various
tumour stages, the stage durations and probability of screen detection
have been estimated using observations from the Dutch cancer
r e g i s t r ya n dt h eD u t c hb r e a s tc a n c e rscreening programme (National
Evaluation Team for Breast cancer screening (NETB), 2009). After a
breast cancer diagnosis, some women may be cured whereas others
may not. The age- and stage-specific probability of cure and the
survival after diagnosis were based on several international sources
(Adami et al, 1986; Carter et al, 1989; Tabar et al, 2000; Michaelson
et al, 2002, 2003; Sant et al, 2003). The improvement in survival after
screen detection was based on the Swedish breast cancer screening
trials (de Koning et al,1 9 9 5 ;T a b a ret al, 2000; Nystrom et al, 2002;
Bjurstam et al, 2003). Model parameters and the procedures of
parameter estimation have been published elsewhere (Groenewoud
et al, 2004). Model outcomes were predicted breast cancer incidence
and mortality without screening, and predicted breast cancer
mortality with screening. From this, the predicted number of
prevented deaths could be derived.
The risk of developing breast cancer due to screening exposure
was estimated using the excess absolute rate (EAR) model by the
BEIR-VII committee (National Research Council of the National
Academies, 2006), who adopted and reparameterised the ‘pooled
analysis’ EAR model by Preston et al (2002). The model is
described as follows:
lðt; d; EÞ¼lðt; 0Þþ
X
i
eðt; di; EiÞ
and
eðt; d; EÞ¼d   148   expð 0:05ðE   30Þþ3:5lnðt=60ÞÞ if to50
eðt; d; EÞ¼d   94   expð 0:05ðE   30Þþlnðt=60ÞÞ if tX50
The incidence l(t, d, E) per 100000 women years is equal to the
predicted baseline incidence without radiation l (t, 0) plus the sum
of all induced breast cancers due to radiation
P
i e (t, di, Ei) at each
screening round. In the equation, d is the glandular dose (mGy),
E is the exposure age and t is the attained age. The risk of
radiation-induced breast cancer increases with younger exposure
age and higher attained age. After age 50, the risk increases less
steeply than before this age, which is probably related to hormonal
changes around the menopause. The dose–response coefficient
(148 before age 50, 94 from age 50) is slightly different from that in
the BEIR-VII model, because an error was made in the
parameterisation of the original Preston model (Preston, personal
communication). The lifetime risk of breast cancer in a situation
with mammography was calculated by multiplying the incidence at
a given age with the survival at that age and cumulating the
products:
Id ¼
X
t
lðt; d1;d2;...E1; E2 ...Þ SðtÞ t ¼ 0...100
The induced breast cancer mortality was calculated by multiplying
the breast cancer incidence at a given age with the survival and
case fatality (p(t)) at that age, and cumulating the products for all
ages:
Md ¼
X
t
lðt; d1;d2;...E1; E2 ...Þ pðtÞ SðtÞ t ¼ 0...100
Age-specific case fatality was derived from MISCAN. Survival was
calculated using a recent life table for Dutch females. We assumed
that cancers that were induced by radiation could become screen
detected, at a similar rate as non-induced breast cancers.
Repeated exposure to low doses such as observed at mammo-
graphy screening are considered to be less harmful than the high
doses that were observed in atomic bomb survivors and women
that were exposed for diagnostics or therapy. Therefore, it has been
suggested that the predicted number of induced breast cancers
and breast cancer deaths at mammography screening should be
divided by a correction factor (the DDREF) (International
Commission on Radiological Protection (ICRP), 1990; National
Council on Radiation Protection and Measurements (NCRP), 1993;
Environmental Protection Agency (EPA), 1999; United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR), 2000; National Institutes of Health (NIH), 2003). In
our paper, we used a DDREF of 1.5, as suggested by the BEIR-VII
Committee (National Research Council of the National Academies,
2006).
Radiation risks and screening benefits were calculated for a
biennial screening program targeting women aged 50–74. The
impact of extending the screening programme to women younger
than 50 years of age was also assessed, by calculating risks and
benefits for various starting ages between age 40 and 50. The
average absorbed glandular dose at mammography screening was
1.3mGy per view (of both breasts), as shown by Zoetelief et al
(2006) among women from four regional breast cancer screening
units in the Netherlands. Two-view mammography is performed at
first screening rounds, while at subsequent rounds a single view is
made. Assuming that women attend all screening rounds, the total
glandular dose would thus be 14 1.3¼18.2mGy at biennial
screening between age 50 and 74. Because regional variations of
between 1.04 and 1.63 mGy per view and a maximum dose of
5 mGy per view (in o1% of all women) were observed (Zoetelief
et al, 2006), we also estimated the radiation risks for a glandular
dose of 1, 2 and 5mGy per view. For women between age 40 and
49, we assumed that the same number of views were made as for
women aged 50–74. The test sensitivity was expected to be 25%
lower than that of older women (International Agency for Research
on Cancer, 2002). We hypothesised that breast cancer mortality
could be reduced by 24% by annual mammography in screened
women of this age group, similar to that observed in the UK Age
Trial (Moss et al, 2006).
Several sensitivity analyses were performed. These include a
calculation of the radiation risk:
  using the BEIR-V and BEIR-VII excess relative risk model
(National Research Council, 1990; National Research Council of
the National Academies, 2006),
  assuming that induced cancers could not be detected by
screening,
  assuming no correction for DDREF,
  assuming a 10-year latency time,
  assuming annual screening for women aged 40–49, and biennial
screening for 50- to 74-year-old women,
  assuming that the test sensitivity for women aged 40–49 is 50%
lower than or similar to that for older women,
  assuming that the effectiveness of screening for women aged
40–49 is 25% lower or 25% higher than that our baseline
estimate.
All effects were calculated for a cohort of 100000 women aged
0–100, measured over their entire lifespan. To separate the
consequences of radiation at younger ages from those at older
ages, we also analysed the effects and radiation risks of a decade of
annual screening starting at age 30 and 40. In all scenarios, a 100%
participation rate was assumed. Besides screening effects, no other
time-dependent changes in breast cancer incidence and mortality
were assumed.
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Without screening, a total of 12289 breast cancers were predicted
to be diagnosed in a population of 100000 women aged 0–100
(Table 1). The radiation that is absorbed at biennial screening
between age 50 and 74 at a glandular dose of 1.3mGy per view
would induce 7.7 extra breast cancers. The ratio of baseline
incidence without screening vs induced incidence would be
1596:1, meaning that per 1596 breast cancers, 1 would be caused
by screening. At a glandular dose of 5mGy per view, the predicted
number of induced breast cancers was 29.6 per 100000 women
aged 0–100, and the ratio of baseline to induced cancers 415:1.
Extension of the lower age limit for screening would further
increase the number of induced cancers, up to 17.1 if women aged
40–74 are screened biennially (1.3mGy per view). In this scenario,
the ratio baseline:induced incidence would be 720:1, ranging
between 936:1 and 187:1 if the glandular dose would be 1 and
5mGy per view, respectively.
The predicted number of breast cancer deaths in a situation
without screening was 4330 per 100000 women (Table 2).
Approximately 26% of those (1121) could be prevented by biennial
screening in the age group 50–74. On the other hand, screening
would cause 1.6 extra breast cancer deaths per 100000 women,
assuming a glandular dose of 1.3mGy per view. The
ratio of baseline mortality without screening vs induced deaths
would be 2641:1. Weighing the number of prevented
deaths against the number of induced deaths, this ratio would be
684:1. A glandular dose of 5mGy per view would increase the
number of induced breast cancer deaths to 6.3, which would
result in a ratio of baseline mortality vs induced deaths of 687:1,
and a ratio of prevented vs induced deaths of 178:1. Screening
from a younger age would further increase the number of induced
deaths. Biennial screening between age 40 and 74, for instance,
would cause 3.7 extra breast cancer deaths at 1.3mGy per view.
The benefit–risk ratio would then be 349 prevented vs 1 induced
death. Increasing the glandular dose to 5mGy per view would
cause 14.4 extra breast cancers deaths, resulting in the least
favourable benefit–risk ratio: 91 prevented vs 1 induced breast
cancer death.
The balance between screening effects and radiation risks is also
dependent on the assumed screening benefit for induced breast
cancers, the assumed latency time and the shape of the dose–
response; that is, whether the model is corrected for a DDREF or
not (Table 3). Using the BEIR-V ERR model (National Research
Council, 1990) instead of the BEIR-VII EAR model had no
substantial effect on radiation risks, but the BEIR-VII ERR model
resulted in substantially higher risk estimates. The number of
induced breast cancer deaths is hardly affected by the assumed
screening effectiveness or test sensitivity for women below age 50.
The number of prevented breast cancer deaths, however, increases
slightly, and is highest when the sensitivity is assumed to be the
same for women younger and older than 50. Most breast cancer
deaths can be prevented in a situation with annual screening
between the ages 40 to 49, and biennial screening between age 50
and 74. However, the extra screening examinations would also
result in the highest number of induced cancer deaths: 5.4 per
100000 women. This resulted in the least favourable benefit–risk
balance: per 259 prevented deaths, one breast cancer would be
induced by screening.
Focussing on the first decade of screening only, annual
screening from age 40 in general would avoid more deaths than
it induces. Even in the unlikely situation that the average radiation
dose would exceed 10mGy per view and the model has under-
estimated the number of induced breast cancer deaths by a
factor of 3, the radiation risks of screening would not outweigh the
benefits (Figure 1A). Annual screening from age 30 would induce
more deaths than it prevents if the average dose would be 7mGy
per view or more, and the radiation risks would be underestimated
by a factor of 3 (Figure 1B). However, screening in this age group
in the Netherlands is only recommended when women are at high
risk for breast cancer, for instance because of an inherited BRCA1
or BRCA2 gene mutation.
Table 1 Induced breast cancer incidence at various radiation doses and screening scenarios
a
Radiation dose (mGy) per view 1 1.3 2 5
Baseline incidence per 100000 women aged 0–100, predicted without screening 12289 12289 12289 12289
Biennial screening ages 50–74
Induced incidence per 100000 women aged 0–100 5.9 7.7 11.8 29.6
Baseline incidence:induced incidence 2075:1 1596:1 1037:1 415:1
Biennial screening ages 48–74
Induced incidence per 100000 women aged 0–100 7.0 9.1 14.1 35.2
Baseline incidence:induced incidence 1747:1 1344:1 874:1 349:1
Biennial screening ages 46–74
Induced incidence per 100000 women aged 0–100 8.3 10.8 16.6 41.5
Baseline incidence:induced incidence 1482:1 1140:1 741:1 296:1
Biennial screening ages 44–74
Induced incidence per 100000 women aged 0–100 9.7 12.6 19.4 48.6
Baseline incidence:induced incidence 1264:1 973:1 632:1 253:1
Biennial screening ages 42–74
Induced incidence per 100000 women aged 0–100 11.3 14.7 22.7 56.6
Baseline incidence:induced incidence 1085:1 835:1 543:1 217:1
Biennial screening ages 40–74
Induced incidence per 100000 women aged 0–100 13.1 17.1 26.3 65.6
Baseline incidence:induced incidence 936:1 720:1 468:1 187:1
Abbreviation: BEIR-VII, 7th Biological Effects of Ionizing Radiation committee.
aAs calculated with the BEIR-VII excess absolute rate (EAR) model corrected with a ‘dose and
dose-rate effectiveness factor’ (DDREF) of 1.5, assuming no latency time and a potential screening benefit for induced breast cancers. For women below the age of 50, the
screening effectiveness was assumed to be comparable to that in the UK Age Trial (Moss et al, 2006) and the test sensitivity was estimated to be 25% lower than that for women
older than 50 years of age. The grey-shaded column represents the baseline and induced breast cancer incidence at the avereage observed glandular dose (1.3 mGy per view) in
the Netherlands.
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a
Radiation dose (mGy) per view 1 1.3 2 5
Baseline mortality per 100000 women aged 0–100, predicted without screening 4330 4330 4330 4330
Biennial screening ages 50–74
Prevented mortality (MISCAN, screening – no screening) 1121 1121 1121 1121
Induced mortality per 100000 women aged 0–100 1.3 1.6 2.5 6.3
Baseline mortality:induced mortality 3434:1 2641:1 1717:1 687:1
Prevented mortality:induced mortality 889:1 684:1 445:1 178:1
Biennial screening ages 48–74
Prevented mortality (MISCAN, screening – no screening) 1172 1172 1172 1172
Induced mortality per 100000 women aged 0–100 1.5 2.0 3.0 7.5
Baseline mortality:induced mortality 2876:1 2212:1 1438:1 575:1
Prevented mortality:induced mortality 779:1 599:1 389:1 156:1
Biennial screening ages 46–74
Prevented mortality (MISCAN, screening – no screening) 1216 1216 1216 1216
Induced mortality per 100000 women aged 0–100 1.8 2.3 3.6 8.9
Baseline mortality:induced mortality 2427:1 1867:1 1213:1 485:1
Prevented mortality:induced mortality 681:1 524:1 341:1 136:1
Biennial screening ages 44–74
Prevented mortality (MISCAN, screening – no screening) 1247 1247 1247 1247
Induced mortality per 100000 women aged 0–100 2.1 2.7 4.2 10.5
Baseline mortality:induced mortality 2057:1 1582:1 1028:1 411:1
Prevented mortality:induced mortality 592:1 455:1 296:1 118:1
Biennial screening ages 42–74
Prevented mortality (MISCAN, screening – no screening) 1275 1275 1275 1275
Induced mortality per 100000 women aged 0–100 2.5 3.2 4.9 12.3
Baseline mortality:induced mortality 1757:1 1351:1 878:1 351:1
Prevented mortality:induced mortality 517:1 398:1 259:1 103:1
Biennial screening ages 40–74
Prevented mortality (MISCAN, screening – no screening) 1302 1302 1302 1302
Induced mortality per 100000 women aged 0–100 2.9 3.7 5.7 14.4
Baseline mortality:induced mortality 1508:1 1160:1 754:1 302:1
Prevented mortality:induced mortality 453:1 349:1 227:1 91:1
Abbreviations: BEIR-VII, 7th Biological Effects of Ionizing Radiation committee; MISCAN¼microsimulation screening analysis.
aAs calculated with the BEIR-VII excess absolute
rate (EAR) model corrected with a dose and dose-rate effectiveness factor (DDREF) of 1.5, assuming no latency time and a potential screening benefit for induced breast
cancers. For women below the age of 50, the screening effectiveness was assumed to be comparable to that in the UK Age Trial (Moss et al, 2006) and the test sensitivity was
estimated to be 25% lower than that for women older than 50 years of age. The grey-shaded column represents the baseline and induced breast cancer mortality at the avereage
observed glandular dose (1.3 mGy per view) in the Netherlands.
Table 3 Induced and prevented breast cancer deaths and the benefit–risk ratio of breast cancer screening under various model assumptions, calculated
for a glandular dose of 1.3mGy per view, for 100000 women aged 0–100
Induced
mortality
Prevented
mortality
Ratio prevented:
induced mortality
Biennial screening ages 50–74 1.6 1121 684:1
Biennial screening ages 50–74 Latency period of 10 years 1.4 1121 805:1
Biennial screening ages 50–74 BEIR-V ERR 1.7 1121 658:1
Biennial screening ages 50–74 BEIR-VII ERR 2.7 1121 419:1
Biennial screening ages 50–74 No screening benefit for induced cancers 2.4 1121 462:1
Biennial screening ages 50–74 No correction for DDREF 2.5 1121 464:1
Biennial screening ages 40–74 3.7 1302 349:1
Biennial screening ages 40–74 Screening effectiveness 50-  25% 3.8 1256 334:1
Biennial screening ages 40–74 Screening effectiveness 50- +25% 3.7 1342 362:1
Biennial screening ages 40–74 Sensitivity 50-50% lower than 50+ 3.8 1225 323:1
Biennial screening ages 40–74 Sensitivity 50- same as 50+ 3.7 1371 373:1
Annual screening ages 40–49 and
biennial screening ages 50–74
5.4 1392 259:1
Abbreviation: BEIR-VII, 7th Biological Effects of Ionizing Radiation committee.
aAs calculated with the BEIR-VII excess absolute rate (EAR) model corrected with a ‘dose and
dose-rate effectiveness factor’ (DDREF) of 1.5, assuming no latency time and a potential screening benefit for induced breast cancers. For women below the age of 50, the
screening effectiveness was assumed to be comparable to that in the UK Age Trial (Moss et al, 2006) and the test sensitivity was estimated to be 25% lower than that for women
older than 50 years of age. The grey-shaded rows represent the baseline scenarios.
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Our study demonstrated that the risk of radiation-induced
breast cancer due to mammography screening is small. Biennial
screening between age 50 and 74 was predicted to cause 7.7 breast
cancers and 1.6 breast cancer deaths per 100000 women aged
0–100, but would also prevent 1121 breast cancer deaths. This
indicates that the radiation risks of regular mammography are
negligible.
Compared with previous estimates of the radiation risk at
mammography screening of 4–23 excess breast cancers (Mattsson
et al, 2000; Law and Faulkner, 2001; Law et al, 2007) and 2–11
extra breast cancer deaths per 100000 women (Beemsterboer et al,
1998; Mattsson et al, 2000; Berrington de Gonzalez and Reeves,
2005), our predictions are relatively small. This may be related to
the mean glandular dose in the Netherlands of 1.3mGy per view,
which is smaller than the average dose of between 1.78 and
2.35mGy previously found in the Netherlands (Beemsterboer et al,
1998), or the dose of between 1.5 and 2.4mGy per view observed in
other countries (Mattsson et al, 2000; Law and Faulkner, 2001;
Young et al, 2005; Hendrick et al, 2010). Furthermore, calculations
were based on one-view mammography at subsequent screening
rounds, but in practice, two-view mammography is increasingly
performed. If we would assume a second view in B50% of all
subsequent screening rounds, as estimated by Duijm et al (2009),
the mean glandular dose would increase to 2mGy per examination
and the number of induced breast cancer deaths to 2.5 per 100000
women. Several screening programmes routinely use two views
(Broeders et al, 2005), which would double the radiation risks
compared with our estimates at 1.3mGy per view.
Our estimates are also lower because a DDREF correction of
1.5 was used to estimate the radiation risk at the low doses
absorbed at mammography screening (National Research Council
of the National Academies, 2006). It was further assumed that all
women with radiation-induced cancers could profit from the
screening programme. In reality, this will not entirely be the case,
because some cancers will become clinically diagnosed in the
interval between two screening rounds, or after women reach the
upper age limit for screening.
Radiation risk estimates involve many uncertainties. Previous
calculations of the risk of mammography screening have
frequently been based on an ERR model (Beemsterboer et al,
1998; Mattsson et al, 2000; Berrington de Gonzalez and Reeves,
2005), but in our study the EAR model was used, following the
recommendations by BEIR-VII and Preston et al (2002). Our
sensitivity analysis showed that the outcomes of the EAR model
were comparable to those of the BEIR-V ERR model but lower than
the BEIR-VII ERR model. The main conclusions did not differ.
Second, different types of radiation may vary in the harm they may
cause. The model that was used in this study was based on
Japanese atomic bomb survivors who were exposed to g-rays and
neutrons, and medically exposed women who received high-energy
X-rays or Ra-226 g-ray radiation for diagnostics or therapy.
Mammography, on the other hand, involves low-energy X-ray
radiation, which may be more biologically effective, although no
clear epidemiological evidence on this is currently available
(National Research Council of the National Academies, 2006).
The estimation of the glandular dose itself is also uncertain, and
may differ by screening age, breast density and breast thickness.
Regional variations in glandular dose of between 1.04 and
1.63mGy per view have been observed in the Netherlands, which
were mainly related to differences in technical conditions (i.e.,
anode-filter combinations) of the screening units (Zoetelief et al,
2006). It may be difficult to distinguish the harm due to exposure
to the natural background radiation from the harm due to
screening. The average natural background dose is 2.4mSv per
year (National Research Council of the National Academies, 2006),
meaning that (assuming that 1 mSv¼1 mGy) the cumulative
glandular dose during 35 years of screening (between age 40 and
75) would be 84mGy (2.4 35). As a comparison, the total
screening dose would be 24.7mGy (1.3mGy 18 screening rounds
between age 40 and 75þ1 extra view at the initial screening
round).
The overall uncertainty in the assessment of radiation risks has
been estimated to be a factor 2–3 (National Research Council of
the National Academies, 2006; Law et al, 2007). Nevertheless, even
if we underestimated the risks by a factor of 3, the benefits of
screening for women aged 50–74 would strongly outweigh the
radiation risks.
Despite the observation that radiation risks increase with
younger exposure age (Preston et al, 2002), screening from age
40 would not severely jeopardise the benefit–risk ratio. Even if the
screening effectiveness would be 25% lower and the radiation dose
twice as high as in the current analysis, the radiation risks would
be small. Our predictions for women between age 40 and 49 are
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Figure 1 (A and B) Prevented and induced breast cancer deaths at a
decade of screening starting at age 40 (A) or age 30 (B), calculated for
100000 women aged 0–100. Calculations were based on the BEIR-VII
excess absolute rate (EAR) model, assuming no latency time. The test
sensitivity for women younger than 50 was assumed to be 25% lower than
that for women older than 50, and the screening effectiveness was
comparable to that in the UK Age Trial (Moss et al, 2006). For both
situations, no ‘dose and dose-rate effectiveness factor’ (DDREF) correction
was applied. Vertical lines represent an uncertainty interval around the
estimated number of induced breast cancer deaths of a factor 3.
Radiation risks vs benefits of mammography screening below age 50
R de Gelder et al
1218
British Journal of Cancer (2011) 104(7), 1214–1220 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ymore favourable than that of Mattsson et al (2000) and Berrington
de Gonzalez and Reeves (2005), who expected a net increase in
breast cancer deaths at a total glandular dose of X50mGy and
a mortality reduction o20% (Mattsson et al, 2000; Berrington de
Gonzalez and Reeves, 2005). The difference may be related to
model choice (EAR instead of ERR). Future developments in breast
cancer screening, such as digital mammography, may further
increase the screening benefits for women below 50 (Pisano et al,
2005), and has the potential to reduce the absorbed radiation dose
by 17% (Hendrick et al, 2010). Our results confirm that the
benefit-risk ratio of screening from age 30 on is very delicate.
Of course, the risk of radiation is just one of the possible harms
of mammography screening. In a decision whether or not to
screen before age 50, the risks of false-positive and false-negative
mammograms, as well as the risk of overdiagnosis should be taken
into account.
CONCLUSION
The radiation risks of mammography screening between age 40 and
74 were predicted to be negligible. From age 30, the balance between
screening benefits and radiation risks would become fragile.
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